About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Key points

EiRx stands to earn milestones and royalties on the successful development of ZYC300. A similar success-based milestone arrangement pertains to the Company's licensing of drug targets to OSI Pharmaceuticals (NASDAQ: OSIP). The Board will update the market if and when such milestones are reached.

EiRx and Almac Diagnostics view the signing of this agreement the first phase of a strategic alliance that is expected to expand as the companies work together to develop enhanced treatments for colorectal cancer.


ERX entered into an agreement with bioMerieux SA, the leading international diagnostics group headquartered in France. Should we enjoy success in our collaborative technical programme we would expect to progress to technology licensing and ultimately to generate milestone payments and revenues from the development of new cancer diagnostics products by bioMerieux.

Efficacy of ERX3722 in breast cancer model
These molecules are currently undergoing further development and optimization for the treatment of breast cancer; a market estimated to be worth $6.2 billion per annum. Other cancer indications will also be sought for these molecules and/or their optimized derivatives.

EiRx's main discovery effort aims to identify novel cancer kinase inhibitors, and several recent third-party licensing deals indicate the impressive valuations being placed on such products at the late preclinical stage. These include Rigel's licensing of the aurora kinase inhibitor R763 to Serono (total potential value of $160M, with $25M upfront), CGI's licensing of the multi-kinase inhibitor CGI1842 to Genentech (total potential value of $500M, with $25M upfront), Plexxikon's licensing of the PLX4032 inhibitor of mutant B-Raf kinase to Roche (total potential value $660M, with $40M upfront) and Piramed's licensing of its PI3-kinase inhibitor programme to Genentech (total potential value of $230M).

I believe this recent licensing activity in EiRx's chosen field bodes well for
EiRx's future prospects, but also indicates the stage of development at which
the Company can expect to secure a significant license deal.

Thanks for the recap driver, more news tomorrow you think ??

Driver do you think the share price will drop or go up the the result reported?

Marcel
Its the new funds that is the problem punters on the other side want jam right now, IMO erx has a lot going on and payments could come at any time or a development announcement that will see the sp surge I will not be selling just adding on any dips ERX looks like a good long term play I was buying at .17 and would do so again if it ever gets there.

Thanks for your opion

Have read the rns and the part that stood out for me was this....

EiRx's main discovery effort aims to identify novel cancer
kinase inhibitors, and several recent third-party licensing deals indicate the
impressive valuations being placed on such products at the late preclinical
stage. These include Rigel's licensing of the aurora kinase inhibitor R763 to
Serono (total potential value of $160M, with $25M upfront), CGI's licensing of
the multi-kinase inhibitor CGI1842 to Genentech (total potential value of $500M,
with $25M upfront), Plexxikon's licensing of the PLX4032 inhibitor of mutant
B-Raf kinase to Roche (total potential value $660M, with $40M upfront) and
Piramed's licensing of its PI3-kinase inhibitor programme to Genentech (total
potential value of $230M).

I believe this recent licensing activity in EiRx's chosen field bodes well for
EiRx's future prospects, but also indicates the stage of development at which
the Company can expect to secure a significant license deal. To reach the late preclinical stage common to the recent license deals listed above, EiRx will
require a minimum of two to three years' further research and development.

RichF
And your point is.

Raising more funding is not a negative, if that is what is needed for further development them let them raise it we will benefit in the end.


Bioprogress recently raised funds with a placing at 50p in sept they stand at nearly 70p

Also ASM raised 26.3m and we didn't even know it was coming, the sp lost a few points now it's on the up.

London UK, 15 December 2006 Antisoma plc (LSE:ASM, US OTC: ATSMY)
today announces that it has raised approximately 26.3 million before
expenses.

I think the MM will milk the share holders trying to bail out this morning.

Where's the potato head gone! Would be interesting to hear their comments.

analyst note coming out shortly

results were very good, milestones confirmed as coming, but we dont know when.
short termers are the ones who will be paying the price.

zzzzzzzzzzzzz

"John K Pool"
13/11/2006 17:14
To
cc

Subject
Re: Shareholder Question





We are looking at producing an analysts note currently We are not
considering going back to the market, if at all, without some very
significant news
John
----- Original Message -----
From:
To: "John K Pool"
Sent: Monday, November 13, 2006 5:10 PM
Subject: Re: Shareholder Question


> John,
>
> Yes I understand this, but my concern is if we dont get some cash soon ERX
> will run out of cash and turn to the market, which I really am hopeing
> this
> will not be the case. I am hopeing the milestone payments will fund us for
> a number of years.
>
> As you know I commented on the marketing, we have changed broker but no
> broker update, I have noted some PI's have asked Seymore pierce why there
> is no broker note, and they say there is none, why not???, this I believe
> is putting many potential investors off.
>
> I look forward to receiving the annual report
>
> Kind regards
>

PH they have confirmed a placing for April 2007 which has to bring into question the above?

"John K Pool"
12/10/2006 09:34
To
cc

Subject
Re: Shareholder Question





Yes it is being chased as we speak
Cheers
john
----- Original Message -----
From:
To: "John K Pool"
Sent: Thursday, October 12, 2006 9:32 AM
Subject: Re: Shareholder Question


> Morning John,
>
> Many thanks for that, I did in fact go through all the news papers, and
> only found a mention in an irish paper, I did see people mention that it
> was in skye news, but I watched and did not see it, oh well.
> Can I ask, what exactly happened to the licence payment from MGI, you did
> mention this last year, I think, also I noted you also said Patent
> applications should be passed within 3-6 months but we have also passed
> that timescale.
>
>
> Many thanks

happy xmas to all

Merry Christmas and look forward to some RNS and not just you PH!

Sounds good laurie ! have a good weekend all :))

I know PH has made this a joke thread through out 2006 well many of us were here before he arrived ERX is not a joke company and should not be seen as a fast buck, ERX is a serous drug company developing some very important therapies for cancer that could one day save the life of any one of our families including ourself's, that's that bit out of the way.

They have collaborations and Intellectual Property agreement with Almac Diagnostics, bioMerieux SA, future milestones and royalties that could run into millions on the successful development of ZYC300. A similar success-based milestone arrangement pertains to the Company's licensing of drug targets to OSI Pharmaceuticals also payments could come from bioMerieux and MGI Pharma Just one small payment from any one of these companies will see the sp surge. The M/Cap is ridiculously small for such a bio company with so much going on IMO erx will have a successful placing next year, a development break through or some milestones payments in 2007 Not a share to be out of Top Up on the dips.

edjodav - 29 Dec'06 - 12:10 - 713 of 713

One of the reasons we delayed was to try and get them in, we are however chasing, but big companies don't seem to work on the same timescales as us, more glacial.
Have a good Christmas
John
----- Original Message -----
From:
To: John K Pool
Sent: Friday, December 22, 2006 12:07 PM
Subject: milestone payments


hi john i sent you an email yesterday asking when results would be out and you told me today but yet they were released yesterday after market close, you stated that you would refer to mentioning anything about milestone payments until the results had been released please would you be so kind as to let me know when you will make a statement relating to this. regards a loyal shareholder eddie davis